Ketamine Combination Therapy: Augmentation Strategies with Existing Treatments

Ketamine combination therapy means using ketamine alongside an existing medication plan or psychotherapy, with prescribing and timing decisions made by the treating clinician. Current evidence supports continuing many standard antidepressants in clinical research settings, but the evidence for specific augmentation pairings is limited. Medication changes, including holding benzodiazepines, should not be made without clinical guidance.

Ketamine can produce rapid antidepressant effects for some people with treatment-resistant depression, but response durability varies. Combination approaches aim to support ongoing treatment and make practical use of any improvement in mood, motivation, or engagement after treatment.

What the evidence supports

Most ketamine depression trials have allowed participants to remain on existing antidepressants. In a randomized trial of ketamine for treatment-resistant major depression, researchers reported that concurrent antidepressant class did not show a significant association with acute response in a post-hoc analysis. Murrough et al. published the trial in Biological Psychiatry.

According to the National Institute of Mental Health, depression treatment can include psychotherapy, medication, or both, and treatment plans should be tailored to the individual. Read the NIMH overview of depression.

That does not establish that every medication pairing improves ketamine outcomes. Much of the combination literature comes from secondary analyses, small studies, and mechanistic hypotheses rather than trials designed to compare combination protocols directly.

Antidepressants, TCAs, and MAOIs

SSRIs and SNRIs are often continued during ketamine treatment. These drugs primarily affect serotonin signaling, while ketamine acts as an NMDA receptor antagonist. Their use together is common in research and clinical practice, but a clinician still needs to review the full medication list, dose changes, side effects, and medical history.

Tricyclic antidepressants may require closer cardiovascular review. Their effects on norepinephrine signaling can matter because ketamine can temporarily raise blood pressure and heart rate. This is a monitoring consideration, not proof that the combination is unsuitable for every patient.

MAOIs call for especially careful prescribing review. Published guidance has described a theoretical concern about additive sympathomimetic effects. The evidence at subanesthetic ketamine doses remains limited, so the appropriate approach is individualized assessment and monitoring rather than a self-directed medication change. For broader context, see this site’s ketamine drug interactions guide.

Mood stabilizers and antipsychotics

Lithium and valproate are relevant in bipolar depression treatment plans. In a bipolar depression trial, ketamine was studied in participants receiving lithium or valproate. Diazgranados et al. reported rapid antidepressant effects in Archives of General Psychiatry. This finding supports the feasibility of studying ketamine in that treatment context, not a universal pairing recommendation.

Lithium has not clearly extended ketamine response in the available randomized evidence. A small trial that started lithium after a successful ketamine infusion did not find a significant benefit over placebo for maintaining response. Its size and timing leave open questions, but they do not justify presenting lithium as a proven consolidation treatment.

Lamotrigine has an unresolved interaction question. It may influence glutamate signaling and can reduce some acute ketamine effects in healthy-volunteer research. Whether it changes antidepressant benefit remains unclear. Antipsychotic combinations are also understudied, so medication-specific review matters more than broad class assumptions.

Benzodiazepines and ketamine

Benzodiazepines may reduce ketamine response for some patients, but the evidence is not settled. One post-hoc analysis found an association between benzodiazepine use and a smaller antidepressant response, while later reviews found mixed results and noted that greater baseline illness severity may help explain the association.

Some clinics ask patients to avoid a benzodiazepine dose on the treatment day when their prescriber considers that safe. That practice is a risk-management decision, not a rule that applies to everyone. People taking benzodiazepines regularly should discuss timing, dose, dependence risk, anxiety symptoms, and seizure history before any adjustment. Read more about ketamine and benzodiazepines.

Psychotherapy integration

Psychotherapy is a practical combination strategy, though the ideal timing is not established. Ketamine-assisted psychotherapy research has proposed scheduling therapy during the days after treatment, when people may be more able to engage with new coping skills or behavioral goals. Evidence is promising but still needs larger controlled trials.

CBT, behavioral activation, and exposure-based approaches each have a different purpose. Behavioral activation may be useful when a person’s main barrier is withdrawal from daily activities. Exposure therapy should be planned by a qualified mental health professional when anxiety or trauma-related symptoms are involved. See the site’s overview of ketamine integration therapy for questions to consider after treatment.

How to evaluate a combination plan

A useful plan identifies one goal, one safety process, and one way to assess response. Ask what problem the added treatment is meant to address: acute symptoms, relapse prevention, therapy engagement, sleep, anxiety, or bipolar mood stability. Then ask how the team will distinguish benefit from side effects or a temporary change in symptoms.

Research gaps

Many proposed combinations remain experimental. Rapamycin and scopolamine have generated research interest, but they are not established consolidation strategies for routine ketamine care. The field needs prospective trials that compare ketamine alone with defined medication and psychotherapy combinations, including studies of timing and longer-term outcomes.

For readers considering treatment, the practical question is not which combination sounds most promising in theory. It is whether the plan fits the diagnosis, current medications, health history, monitoring needs, and access to continuing mental health care. Visit ketamine research and evidence for a broader review of what is known and what remains uncertain.